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Abstract
EGFR and cMET cross-talk is involved in breast cancer (BC) progression and resistance to
different targeted therapies, however little is known about the co-expression patterns of
EGFR and cMET or its prognostic significance in BC. Protein levels of EGFR, cMET and
their phosphorylated proteins were measured in 825 BC samples using reverse phase pro-
tein array (RPPA). Given unimodal distribution of proteins, the median was selected as a
cut-off after sensitivity analyses. Kaplan-Meier survival curves were used to estimate
relapse-free (RFS) and overall survival (OS). Cox-proportional hazards models were uti-
lized to determine associations between EGFR and cMET with outcomes. Mean age was
58 years with 457 (55%) hormone receptor (HR) positive, 211 (26%) triple-negative (TN)
and 148 (18%) HER2 positive tumors (HER2+). HER2+ was associated with higher EGFR
expression and phosphorylation, compared to HR and TN (p<0.05). High EGFR expression
was associated with higher phosphorylated-cMET (p-cMET) but not cMET (ANOVA p-
cMET p < 0.001; cMET p = 0.34). The same association was found with high phosphory-
lated-EGFR (p-EGFR) group at Tyr992 and Tyr1068 (both p < 0.001). High expressions in
either of two p-EGFRs were linked with higher cMET as well (all p<0.001). For the TN sub-
type, high expression in EGFR and p-EGFR at Tyr992 but not at Tyr1068 was associated
with higher p-cMET (p<0.00, p = 0.012, p = 0.4 respectively). Only high expression in p-
EGFR at Tyr992 was linked with higher expression of cMET (p = 0.02). In contrast, among
HER2 subtype, high expression in p-EGFR at Tyr1068 but not at Tyr992 was associated
with higher cMET and p-cMET (cMET p = 0.023;p-cMET p<0.001). Four subgroups of
patients defined by dichotomized EGFR/p-EGFR and cMET/p-cMET level demonstrated no
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significant differences in survival. In multivariate analyses, neither cMET nor EGFR expres-
sion/activation was found to be an independent prognostic factor in survival outcome.
Introduction
Breast cancer is the most common invasive cancer and the second leading cause of cancer
death in women worldwide[1]. Metastatic disease is still associated with a poor 5-year survival
rate despite recent advances in therapy[2]. Improving our understanding of the molecular
pathways in carcinogenesis and targeted therapeutics is extremely important in trying to over-
come disease resistance mechanisms and to improve patients prognosis[1].
In the mid-1980’s, the proto-oncogeneMET (on chromosome 7q31) was characterized and
shortly thereafter the receptor tyrosine kinase (RTK) and its ligand, the hepatocyte growth factor/
scatter factor (HGF/SF), were described[3]. cMET, a transmembrane α/β heterodimer protein
receptor, dimerizes and undergoes autophosphorylation upon binding of HGF. Consequently,
proliferative intracellular downstream pathways are activated, such as the Ras-Erk/MAPK and
the PI3K-Akt cascades, and promote invasive growth and apoptosis inhibition[4].
The role of HGF/SF andMET in cancer has been brought to light by several studies. The
normally tightly regulated HGF/MET signaling axis is altered at multiple levels in tumorigene-
sis[5]. Transcriptional deregulation constitutes one the most important mechanisms to disease
modulation. However, other alterations such as genomic amplification, activating point muta-
tions, inadequate degradation and receptor crosstalk also may contribute[6]. Aberrations in
the cMET pathway are also thought to play a role in the progression and invasive growth of
several malignancies such as lung, kidney, head and neck, breast, and colorectal cancers[7–10].
Multiple studies have demonstrated a strong relationship between HGF/MET signaling and
breast cancer progression. MET overexpression has been associated with an invasive pheno-
type during breast cancer progression in vivo and in animal models[8, 11]. Elevated tyrosine
phosphorylation of cMET has been described in basal-like tumors[12]. We have previously
reported that both cMET expression and phosphorylation were associated with worse out-
comes, including inferior overall survival in all BC subtypes[13]. For instance, patients with
high cMET had significantly higher risk of recurrence (HR: 2.06, P = 0.03) and death (HR:
2.81, P = 0.02). Our group also demonstrated that heavily pretreated metastatic BC patients
who were found to displayMETmutations or amplifications had frequent high-grade histol-
ogy, higher metastatic disease burden, and inferior outcomes during phase I clinical trials[14].
“RTK coactivation” and “oncogene switching” are two important mechanisms that cancer
cells utilize to evade normal cellular processing and clearance. Therefore, chemo-resistance and
tumor progression can result from this coactivation[15]. Functional cross talk betweenMET and
other signaling pathways, such as EGFR, ERBB2 and insulin like growth factor 1 receptor are
examples from this interaction. EGFR, cMET and their cross talk play an important role in can-
cer progression and development of resistance to different targeted therapies[16, 17]. In fact,
acquired resistance to gefitinib, an EGFR tyrosine kinase inhibitor, can be mediated byMET
amplification in patients with non-small cell lung cancer (NSCLC)[18, 19]. In HER2-overexpres-
sing breast cancer cells, MET aberrations also contribute to trastuzumab resistance [20]. In addi-
tion, basal BC cell lines demonstrated differential responsiveness to small molecule inhibitors of
cMET and EGFR and the magnitude of response correlated with the degree of target phosphory-
lation[12]. Based on these results, EGFR and cMET dual blockade has been proposed as an
attractive targeted therapy for BC[15]. This approach suggests that inhibiting co-activated net-
work kinases may enhance efficacy and overcome resistance mechanisms.
EGFR and cMET Expression and Phosphorylation in Breast Cancer
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However, little is known about the co-expression patterns of EGFR and cMET in human BC
and its prognostic significance. We hypothesized that EGFR and cMET might be co-expressed
or co-activated in BC resulting in adverse survival outcomes. Using functional proteomic pro-
filing we investigated the association between the expression pattern of both EGFR/cMET and
p-EGFR/cMET proteins and survival outcome in all subtypes of BC.
Methods
Patient Material
Fine needle aspirates or mastectomy samples from 825 primary invasive BC were obtained.
The samples were previously collected from tumor specimens in patients treated at the Univer-
sity of Texas MD Anderson Cancer Center between 1986 and 2007. Institutional Review Board
(IRB) of the University of Texas MD Anderson Cancer Center approved the protocol and spec-
imen obtained from repository. The corresponding clinical data was obtained from the Breast
Cancer Management System database at our institution. Electronic chart review supplemented
deficient information from the medical database. Patient records/information including all
specimens were anonymized and de-identified prior to analysis.
Samples were categorized into three clinically relevant BC subtypes by immunohistochemis-
try (IHC) for estrogen receptor (ER) and progesterone receptor (PR) status and by IHC or fluo-
rescent in situ hybridization (FISH) for HER2 status as per American Society of Clinical
Oncology and College of American Pathologists (ASCO/CAP) guidelines[21]. Hormone recep-
tor-positive (HR+) tumors were ER-positive and/or PR-positive and HER2-negative. Corre-
spondingly, HER2-positive (HER2+) group included all HER2 positive tumors, irrespective of
hormone receptor status. Triple negative (TN) subgroup comprised all cases with ER/PR and
HER2 status negative.
Reverse Phase Protein Microarray (RPPA)
RPPA was performed from proteins extracted from human tumors in our laboratory, as
described previously[22]. Lysis buffer was used to lyse frozen tumors via homogenization.
Tumor lysates were normalized to 1 μg/μL concentration using bicinchoninic acid assay and
boiled with 1% SDS, and the supernatants were manually diluted in six or eight 2-fold serial dilu-
tions with lysis buffer. An Aushon Biosystems (Burlington, MA) 2470 arrayer created 1,056 sam-
ple arrays on nitrocellulose-coated FAST slides (Schleicher & Schuell BioScience, Inc.) from the
serial dilutions. A slide was then probed with validated primary cMET and p-cMET antibodies
(Cell Signaling Technology, Danvers, MA). The signal was amplified using a DakoCytomation–
catalyzed system. The antibodies for cMET (Mouse) and p-cMET (Rabbit, Y1235) were used at a
dilution of 1:250 for RPPA. A secondary antibody was used as a starting point for amplification.
The representative RPPA slide is shown in the supporting information (S1 Fig).
The slides were scanned, analyzed, and quantitated using Microvigene software (Vigene-
Tech Inc.) to generate serial dilution–signal intensity curves for each sample. A representative
natural logarithmic value of each sample curve on the slide (curve average) was then used as a
relative quantification of the amount of each protein in a given sample. The level of cMET and
p-cMET in each sample was expressed as a log mean centered value, after correction for protein
loading, using the average expression levels of over 150 proteins as previously described[22].
Statistical Methods
Boxplots were created for original and log2 transformed expressions of total cMET and p-
cMET according to BC subtypes. The original expressions were right-skewed. However, the
EGFR and cMET Expression and Phosphorylation in Breast Cancer
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log2 transformation data was normally distributed. Hence, all following statistical analyses
were generated with the log2 transformation of the original expression values. All tests were
two-sided. P values less than 0.05 were considered statistically significant. Statistical analyses
were done with R statistical software version 2.12.0 (R Development Core Team, Vienna,
Austria).
Mean and standard deviations were generated for total cMET and p-cMET by tumor sub-
type. Given unimodal distribution of proteins, median was selected as a cut-off after sensitivity
analyses. Overall survival (OS) was measured from the date of diagnosis to the date of death or
lost to follow-up. Relapse-free survival (RFS) was defined from the time of diagnosis to first
relapse. Median RFS and OS were estimated nonparametrically with the use of Kaplan-Meier
curves by levels of total cMET/EGFR and p-cMET/EGFR expression and compared by the log-
rank statistic. Cox proportional hazards models were fit to determine associations of EGFR
and cMET with outcomes after adjustment for other clinical characteristics, such as age, tumor
stage, nodal status, receptor subtype and histologic grade.
Results
EGFR and cMET Expression and Phosphorylation Patterns
Mean age of the patient population was 58 years. There were 457 (55%) HR+, 211 (26%) triple-
negative (TN) and 148 (18%) HER2+ tumors. The HER2+ subgroup was found to display
higher EGFR expression and phosphorylation, compared to HR+ and TN subtypes (p<0.05).
Table 1 demonstrates the association between the expression levels of EGFR/p-EGFR and
the cMET/p-cMET (ANOVA test used by the dichotomized expression groups in high and low
expression levels). High EGFR expression was associated with higher p-cMET, but not cMET,
compared to the low expression group (ANOVA p-cMET p<0.001, MET p = 0.34). EGFR
expression also correlated with p-cMET in HR + and TN subgroups, but not in the HER2+ sub-
group. The expression of both p-EGFR (Tyr992 and Thy1069) correlated with the expression
of p-cMET (p<0.01) in the overall sample and the HR+ subtype.
However, the correlation between p-EGFR and cMET/p-cMET was distinct between TN
and HER2 subgroups. The expression of p-EGFR Tyr992 was significantly associated with
both cMET and p-cMET among TN cases (p<0.05), but not among HER2 positive breast can-
cer. On the other hand, p-EGFR Tyr1068 expression correlated only with HER2 positive breast
cancer cases (p<0.05) and not with TN. These results suggest possible association between co-
activation patterns of EGFR and cMET and the subgroups of breast cancer evaluated.
Fig 1 & Fig 2 exhibit the relationship of EGFR and cMET expression in a different visual
fashion, using the dot plots and Spearman’s correlation coefficients as an indicator for the
strength in association respectively. Strong associations were observed, as expected, between
EGFR and p-EGFR, and between cMET and p-cMET. The strongest association was found
between the two p-EGFRs (Spearman’s coefficient = 0.71). Interestingly, the association
Table 1. Patterns of correlation between EGFR and cMET expression and phosphorylation in all breast cancers and subtypes.
All HR TN HER2
cMET p-cMET cMET p-cMET cMET p-cMET cMET p-cMET
EGFR - + - + - + - -
p-EGFR Tyr992 - + + + + + - -
p-EGFR Tyr1068 - + + + - - + +
+ = statistically signiﬁcant positive association; - = no statistically signiﬁcant association
doi:10.1371/journal.pone.0152585.t001
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between the total expression and phosphorylation was stronger in cMET, when compared to
EGFR. The correlation coefficients between EGFR/p-EGFR and cMET/p-cMET are low in
numbers, reflecting weak associations between the two receptors.
Survival Outcomes
Patients were divided into four different groups by dichotomized EGFR and cMET expression
status (high,>50% and low,<50%): ‘high-high’, ‘high-low’, and ‘low-high’, and ‘low-low’
groups. The same approach was used for two p-EGFR and p-cMET levels resulting in six differ-
ent paired combinations. Kaplan-Meir survival analyses revealed that none of the combina-
tions within the four comparison groups had a statistically significant difference in survival
outcomes. Fig 3 demonstrates no meaningful difference in RFS among the four groups by
EGFR and cMET expression or phosphorylation status, except for p-EGFR at Tyr1068. Patients
with tumor samples that had low p-EGFR at Tyr992 and high cMET experienced favorable
RFS (log rank test p = 0.034). Fig 4 also illustrates no significant difference in OS among the
different groups mentioned above. The same method was used to compare RFS and OS in sub-
groups with different levels of expression of EGFR/p-EGFR and cMET/p-cMET among HR+,
HER2+ and TN BCs. Again, no difference in survival was found in these subgroup analyses.
Fig 1. Boxplot of cMET and p-cMET by EGFR phosphorylation. The boxplots of expression and phosphorylation values of cMET with different expression
levels of EGFR.p1068 in HER2 positive breast cancers is shown. The cutoffs of EGFR.p1068 expression levels were based on median or tertiles of the
expression values of EGFR.p1068. The ANOVA p-values testing comparison significance are shown.
doi:10.1371/journal.pone.0152585.g001
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Multivariate Cox proportional hazard model was used to assess the risk of relapse and over-
all survival in patients with different EGFR/cMET expression and activation patterns after con-
trolling for demographic and clinico-pathological variables including age, tumor stage, nodal
status, receptor subtype and histologic grade. The levels of p-cMET, EGFR, and two p-EGFRs
did not show significant association with any survival outcomes. After multivariate analyses,
neither cMET nor EGFR expression or activation was found to be an independent prognostic
factor in survival outcome.
Discussion
We found that EGFR and cMET are frequently co-expressed and/or co-activated in human BC
and this pattern varied according to BC subtypes. Furthermore, EGFR (or p-EGFR) was more
likely to correlate significantly with p-cMET than with un-phosphorylated cMET.
Fig 2. Pairwise scatter plot of EGFR and cMET and their phosphorylated forms in all breast cancers. The upper triangle shows the Spearman
correlation coefficients between pairs of proteins.
doi:10.1371/journal.pone.0152585.g002
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Fig 3. Relapse-free survival of breast cancer patients by EGFR and cMET/p-cMET status. Kaplan-Meier RFS in all breast cancers; Samples were
grouped by expression levels of EGFR and cMET or their phosphorylated forms (Low: below median High: above median).
doi:10.1371/journal.pone.0152585.g003
EGFR and cMET Expression and Phosphorylation in Breast Cancer
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Fig 4. Overall survival of breast cancer patients by EGFR and cMET/p-cMET status. Kaplan-Meier OS in all breast cancers; Samples were grouped by
expression levels of EGFR and cMET or their phosphorylated forms (Low: below median High: above median).
doi:10.1371/journal.pone.0152585.g004
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The HER2+ subtype was found to display higher EGFR expression and activation compared
to other subtypes. The TN subgroup had high expression of EGFR and p-EGFR at Tyr992.
In our cohort, co-expression or co-phosphorylation of cMET and EGFR were not associated
with adverse survival outcomes. However in TNBC tumors, co-expression of MET and EGFR
has been linked to significantly worse DFS and a trend towards worse OS compared to expres-
sion of EGFR alone[23]. In our study, cMET was found to be an independent prognostic factor,
irrespective of EGFR expression or phosphorylation status, with higher cMET expression asso-
ciated with adverse outcome. A meta-analysis of 21 published studies between 1998 and 2014,
comprising a total of 6010 cases, showed that c-Met overexpression is a statistically significant
adverse predictor of RFS and OS in unselected breast cancer[24].
A relationship between higher EGFR expression and decreased survival in BC patients has
been described as well as an association between EGFR expression and undifferentiated tumor
cells[25]. The evaluation of EGFR and HER2 expression by IHC among 105 BC samples
showed that EGFR staining was associated with elevated rates of cell proliferation (measured
by percentage of Ki67 positive cells). EGFR expression was associated with HER2 expression
by immunohistochemistry and worsened patient outcome, as well as hormone insensitivity in
moderately EGFR positive samples[26]. Furthermore, EGFR expression was associated with
loss of endocrine sensitivity in BC[27, 28]. These results corroborate the notion that EGFR
mediates important pathways related to tumor aggressiveness and lack of response to therapy.
Consequently, breast cancer tumors overexpressing EGFR might be associated with unfavor-
able survival outcomes.
Our results suggest possible distinct interactions and co-activation patterns of EGFR and
cMET among the subgroups of breast cancer. Similar findings between these pathways have
also been described in other tumor types. In a glioblastoma xenograft cell model [29], elevated
levels of mRNA HGF and cMET were detected in the mesenchymal subtype of glioblastoma, a
more aggressive form of this disease. Activation of cMET and HGF expression was found in
tumors with an activating mutation in EGFR. Also, in anaplastic thyroid carcinoma cell lines,
constitutive activation of cMET was found simultaneously with elevated expression of EGFR.
Additionally, an EGFR tyrosine kinase inhibitor was capable of de-activating EGFR pathway
and down-regulating cMET expression[30]. This crosstalk between EGFR and cMET was one
of the mechanisms proposed to explain the constitutive activation of cMET in the absence of
its ligand, HGF[31]. It is suggested that TGFα pathway and the autocrine activation of EGFR,
leading to tumor growth, apoptosis inhibition and metastasis play a role in this process.
In our study, after multivariate analyses controlling for various clinicopathological variables,
cMET expression was not found to be an independent prognostic factor in survival outcome.
This contrasts with previous research findings in BC, which clearly demonstrated that cMET
alterations were associated with unfavorable survival outcomes in BC. It is unclear whether this
is due to random effect or limited sample size.
Poorly differentiated and invasive BC cell lines with increased motility and invasiveness
were associated with high levels of cMET receptor[32]. Thus, our group evaluated levels of
cMET and p-cMET in 257 samples by RPPA and demonstrated that both cMET and p-cMET
were independent prognostic factors for RFS (HR 2.44, 95% confidence interval (CI): 1.34–
4.44, P = 0.003) and also for OS (HR: 3.18, 95% CI: 1.43–7.11, P = 0.003).[13] Furthermore, in
a heavily pretreated metastatic BC patient cohort (those referred to our phase I oncology
department), tumors harboringMET aberrations were found to have unfavorable survival out-
comes, compared to those withoutMET alterations[14], corroborating our findings that cMET
alteration is a poor prognostic factor.
Our results demonstrated that the TN subtype had high expression of EGFR and p-EGFR at
Tyr992, which was associated with higher expression of cMET. The significance of EGFR
EGFR and cMET Expression and Phosphorylation in Breast Cancer
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expression in TNBC and its prognostic relevance are of particular interest in this subgroup of
patients.
EGFR protein expression, gene copy number alteration and mutation in the exons 18 to 21
were examined in 151 cases of TNBC patients and these findings were correlated with clinical
outcomes[33]. High EGFR copy number, but not EGFR mutation, correlated with EGFR pro-
tein overexpression, which was found in 95 (64%) of the cases. Patients whose tumors had
EGFR amplification experienced poor disease-free survival, suggesting that this marker might
be useful for predicting outcomes in these patients. Breast tumors expressing EGFR presented
higher proliferation rates and were more likely to be grade III and estrogen receptor negative
[34]. These results suggested a role for EGFR in the pathogenesis of TNBC and provided ratio-
nale for the clinical investigation of anti-EGFR monoclonal antibodies (i.e. cetuximab) in the
treatment of TNBC. A phase II trial randomized 115 patients to receive cetuximab plus cis-
platin or cisplatin alone[35]. Overall response rate was 20% for combination therapy compared
with 10% for cisplatin monotherapy (OR, 2.13; 95% CI, 0.81 to 5.59; P = .11). Cisplatin plus
cetuximab also resulted in longer PFS compared with cisplatin alone (median, 3.7 v 1.5 months;
HR 0.67; 95% CI, 0.47 to 0.97; P = .032).
However, other trials that combined cetuximab with other chemotherapeutic agents, such
as carboplatin[36] and ixabepilone[37], failed to demonstrate a significant benefit with combi-
nation therapy.
Overall, our results demonstrate that EGFR and cMET are either frequently co-expressed or
co-activated in human BC. Multivariate analyses demonstrated that neither cMET nor EGFR
expression or activation was found to be an independent prognostic factor in survival outcome.
Future clinical trials designed to recruit this particular group of patients are needed.
Supporting Information
S1 Fig. Reverse phase protein assay (RPPA) slide. A representative figure of reverse phase
protein assay (RPPA) slide is shown.
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